keyword
MENU ▼
Read by QxMD icon Read
search

Pimavanserin

keyword
https://www.readbyqxmd.com/read/30004964/pimavanserin-for-psychotic-symptoms-in-people-with-parkinsonism-a-second-chart-review
#1
Joseph H Friedman
INTRODUCTION: Pimavanserin (Pim) is a 5HT2A inverse agonist that is the only Food and Drug Administration-approved treatment for Parkinson disease (PD) psychosis. The published open-label experience is limited. METHODS: This report is a chart review of all patients who were started on the drugs since the one earlier report on 15 patients. All patients were included, whether or not they completed 6 weeks of treatment, the time required for maximum benefit found in the published phase 3 trial...
July 13, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29955532/treatment-of-psychotic-symptoms-in-patients-with-parkinson-disease
#2
Jack J Chen
Persistent psychotic symptoms will develop in up to 60% of patients with Parkinson disease (PD). The initial approach to the management of PD psychosis (PDP) begins with addressing concurrent systemic conditions associated with psychotic behavior, such as delirium, medical conditions (eg, infections), psychiatric disorders (eg, major depression with psychotic symptoms, mania, schizophrenia), and substance misuse or withdrawal. A review of current medications is recommended, and medications that may trigger psychotic symptoms should be eliminated...
November 2017: The mental health clinician
https://www.readbyqxmd.com/read/29955528/pimavanserin-nuplazid%C3%A2-for-the-treatment-of-parkinson-disease-psychosis-a-review-of-the-literature
#3
Katie T B Touma, Daniel C Touma
Introduction: Pimavanserin (Nuplazid™) is an atypical antipsychotic currently indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. The antipsychotic effects of this new agent are believed to occur via selective inverse agonist activity at serotonin 5-HT2a receptors. Methods: Study authors completed a literature review of 2 published randomized controlled trials of pimavanserin for the treatment of Parkinson disease psychosis...
September 2017: The mental health clinician
https://www.readbyqxmd.com/read/29739555/pimavanserin-evaluated-by-the-fda
#4
Paul Webster
No abstract text is available yet for this article.
May 5, 2018: Lancet
https://www.readbyqxmd.com/read/29497575/pimavanserin-a-novel-drug-approved-to-treat-parkinson-s-disease-psychosis
#5
REVIEW
Amanda K Kitten, Sarah A Hallowell, Stephen R Saklad, Kirk E Evoy
Objective : Pimavanserin is the first United States Food and Drug Administration (FDA)-approved treatment for Parkinson's disease psychosis (PDP). This article reviews the safety, efficacy, and pharmacology data for pimavanserin and its role in therapy. Method of Research: Initial literature sources were identified via MEDLINE search (1946-September 2016) of pimavanserin and ACP-103 (original molecular designation). Reference review and search of FDA.gov and clinicaltrials.gov yielded additional studies. English-language studies of pimavanserin for PDP were evaluated...
February 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29494265/pharmacological-interventions-for-psychosis-in-parkinson-s-disease-patients
#6
REVIEW
Joseph H Friedman
Psychosis is a common problem for people treated for Parkinson's disease. The syndrome is quite stereotypic, with hallucinations being the most common, followed by delusions. While the hallucinations are usually not very bothersome, the delusions are typically paranoid in nature. Treatment is often, but not always, required. Areas covered: This article reviews the therapeutic approaches of this syndrome focusing on drug treatments used once contributory factors have been removed. This includes a review of the evidence supporting the use of clozapine and, most recently, pimavanserin, the first drug with antipsychotic efficacy that has no effect on dopamine...
April 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29452684/evaluation-of-the-safety-tolerability-and-efficacy-of-pimavanserin-versus-placebo-in-patients-with-alzheimer-s-disease-psychosis-a-phase-2-randomised-placebo-controlled-double-blind-study
#7
Clive Ballard, Carol Banister, Zunera Khan, Jeffrey Cummings, George Demos, Bruce Coate, James M Youakim, Randall Owen, Srdjan Stankovic
BACKGROUND: Pimavanserin is a selective 5-HT2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved for psychosis in patients with Alzheimer's disease. Therefore, we aimed to evaluate the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis. METHODS: We did a phase 2, randomised, double-blind, placebo-controlled, single-centre (with multiple affiliated nursing home sites across the UK) study...
March 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29452674/pimavanserin-for-patients-with-alzheimer-s-disease-psychosis
#8
Lon S Schneider
No abstract text is available yet for this article.
March 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29404067/development-of-a-uplc-ms-ms-method-for-determination-of-pimavanserin-tartrate-in-rat-plasma-application-to-a-pharmacokinetic-study
#9
Shixiao Wang, Yang Wang, Shuang Gao, Yuanyuan Zhang, Hanpei Wang, Longshan Zhao, Kaishun Bi, Shaojie Wang, Xiaohui Chen
A simple, rapid and sensitive method based on an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) has been developed and validated for the determination of pimavanserin in rat plasma. The analyte was extracted by protein precipitation with methanol and separated on an ACQUITY BEH C18 column (100 × 2.1 mm, 1.7 µm; Waters, USA), with an isocratic elution of acetonitrile-water containing 10 mM ammonium acetate (70:30, v/v), at a flow rate of 0.2 mL/min for 2.5 min. The analyte and clarithromycin (the internal standard) were detected and quantified in positive ion mode using multiple reaction monitoring transitions at m / z 428...
December 2017: Journal of Pharmaceutical Analysis
https://www.readbyqxmd.com/read/29374325/treating-hallucinations-and-delusions-associated-with-parkinson-s-disease-psychosis
#10
REVIEW
Shyam C Panchal, William G Ondo
PURPOSE OF REVIEW: We discuss features of Parkinson's disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. RECENT FINDINGS: Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment...
January 27, 2018: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29185820/delusional-misidentification-in-parkinson-s-disease-report-of-two-cases-and-a-review
#11
REVIEW
Neal Hermanowicz
Syndromes of delusional misidentification consist of disordered familiarity and have been reported in diverse diagnoses, including Parkinson's disease. Although the most common delusional misidentification is Capgras syndrome, in which the sufferer believes a familiar person has been replaced by an identical imposter, other forms have been also described. The pathogenesis of delusions of misidentification appears to require dysfunction of or connection to a left cerebral cortical area involved in recognition of familiarity, and also right frontal cortex serving belief evaluation...
March 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29185542/pimavanserin-a-novel-therapeutic-option-for-parkinson-disease-psychosis
#12
REVIEW
Trevor Hawkins, Brian D Berman
Purpose of review: In April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. Recent findings: Pimavanserin acts as an inverse agonist at serotonin 5-HT2A receptors and has negligible effects on other receptors, thereby avoiding the D2 receptor antagonism that can potentially worsen motor symptoms...
April 2017: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/29185537/erratum-pimavanserin-a-novel-therapeutic-option-for-parkinson-disease-psychosis
#13
(no author information available yet)
[This corrects the article on p. 157 in vol. 7.].
August 2017: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/29160144/parkinson-s-disease-psychosis-presentation-diagnosis-and-management
#14
Ruth B Schneider, Julia Iourinets, Irene H Richard
Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms. Psychosis is a common feature of Parkinson's disease. Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions. PDP is associated with reduced function and quality of life. The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia...
December 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29105858/investigation-of-metabolic-profile-of-pimavanserin-in-rats-by-ultrahigh-performance-liquid-chromatography-combined-with-fourier-transform-ion-cyclotron-resonance-mass-spectrometry
#15
Wenying Wu, Yanjie Chu, Shixiao Wang, Xiaoyang Sun, Jingjing Zhang, Yannian Wang, Xiaohui Chen
RATIONALE: Pimavanserin, a selective serotonin 2A receptor inverse agonist, is a promising candidate for treating Parkinson's disease psychosis. Our previous study revealed that there might be the presence of extensive metabolites of pimavanserin in rats. However, the metabolic fate of pimavanserin in vivo remains unknown. Thus, it is essential to develop an efficient method to investigate the metabolic profile of pimavanserin in rats. Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS) to date has the highest mass measurement accuracy and resolution of any mass spectrometry platform...
February 15, 2018: Rapid Communications in Mass Spectrometry: RCM
https://www.readbyqxmd.com/read/29098976/pimavanserin-for-the-treatment-of-parkinson-s-disease-psychosis-number-needed-to-treat-number-needed-to-harm-and-likelihood-to-be-helped-or-harmed
#16
Leslie Citrome, James C Norton, Kathy Chi-Burris, George Demos
OBJECTIVE: Our aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5-HT2A receptor inverse agonist/antagonist indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP), using the metrics of number needed to treat (NNT) and number needed to harm (NNH). METHODS: Categorical efficacy and tolerability data were extracted from the clinical trial databases of the double-blind placebo-controlled studies of pimavanserin in persons with PDP...
November 3, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29047301/pimavanserin-novel-pharmacotherapy-for-parkinson-s-disease-psychosis
#17
Zeyad T Sahli, Frank I Tarazi
Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Areas covered: This review focuses on the preclinical discovery of pimavanserin. It analyzes the pharmacological, behavioral and molecular mechanisms of pimavanserin and their contribution to the therapeutic advantages of the drug as reported in published preclinical and clinical studies, press releases and product labels. Expert opinion: Pimavanserin exhibits a unique pharmacological profile with nanomolar affinity at serotonin 5-HT2A and 5-HT2C receptors...
January 2018: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/28880354/-pimavanserin-a-new-treatment-for-the-parkinson-s-disease-psychosis
#18
J H Duits, M S Ongering, H J M Martens, P F J Schulte
Clozapine is an effective drug for treating psychosis in Parkinson's disease (PDP) and is registered as such in the Netherlands. However, clozapine can have adverse effects, including agranulocytosis. The new drug pimavanserin was recently registered in the United States for the treatment of PDP.<br/> AIM: To review the literature on pimavanserin and discuss the position it currently occupies in the Netherlands as a potential treatment for PDP.<br/> METHOD: Systematic search of the literature.<br/> RESULTS: We found reports on four randomised controlled trials (RCTs), one review and six articles about the pharmacokinetics and pharmacodynamics of pimavanserin...
2017: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/28817967/pimavanserin-a-novel-antipsychotic-for-management-of-parkinson-s-disease-psychosis
#19
REVIEW
Yasaman Kianirad, Tanya Simuni
Parkinson's disease psychosis (PDP) may develop in up to 60% of Parkinson's patients and is associated with increased morbidity and mortality. It also correlates with depression and dementia, and can contribute to caregiver stress and burnout. Pimavanserin is the first FDA approved drug for the treatment of hallucinations and delusions associated with PDP. Areas covered: For this review, a MEDLINE literature search (via PubMed) and information provided by ACADIA Pharmaceuticals were used. This review will discuss the pathophysiology and current management of PDP...
November 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28802934/psychosis-in-parkinson-s-disease
#20
REVIEW
Dominic H Ffytche, Dag Aarsland
Although illusions, hallucinations and delusions did not play a prominent role in James Parkinson's original clinical descriptions, the longitudinal view of disease progression he advocated has important lessons for the study of such symptoms today. A focus on longitudinal progression rather than individual symptoms led to the concept of PD psychosis-a spectrum of positive symptoms in Parkinson's disease. The publication of criteria for PD psychosis in 2007 helped unify the disparate set of symptoms, raising their profile and resulting in a rapid expansion of literature focussing on clinical aspects, mechanisms, and treatment...
2017: International Review of Neurobiology
keyword
keyword
109330
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"